Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
about
The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic reviewTreatment options for patients with triple-negative breast cancerMaintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumabInfluence of Alternative Tubulin Inhibitors on the Potency of a Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate: Influence of incorporating an internal/integral disulfide bond structure and AlternativeMechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast CancerA pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.Targeted therapies in breast cancer: New challenges to fight against resistance.Benefit-risk assessment of bevacizumab in the treatment of breast cancer.Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients.Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3).High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer.Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients.Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
P2860
Q26824086-C48B9E29-F831-4CE4-AF43-A949AE4B45DEQ34331406-9486B8C1-6B1F-40CB-924E-C8BFB08BB6BAQ34452673-3A6D690C-FF63-444B-97C6-F05613D8BDCEQ35842769-764AC653-F18A-468E-BE6C-5D62C7EB49A2Q35892045-319FADA2-4742-4EEA-892D-18BE3D128AE7Q35977527-B05DF019-6FF6-40CA-B390-B74CFFED832CQ36076814-42502CC2-BC97-47C2-AA3A-90EF8DBB260AQ37743048-BB06468F-E036-43DE-A998-E06AE4F9FA46Q37963955-4D0D8E72-F702-4C31-A731-2E7C6D2D2BD7Q38040419-F6223ABD-4B99-4879-9D74-DC89E9EDB1A3Q40678981-F18CAAF2-1820-4E90-936A-63E32AFC0B82Q40847140-704B976D-966F-4C3D-B81E-3EE0BED96DAFQ45142013-577ACF53-7D80-4271-BC12-2239054F7094Q49784365-FC5CE67F-F6F4-443C-BBC2-1281A7466C3BQ54459895-8E6CE086-9A60-4D12-89E5-AD234F613F7F
P2860
Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Bevacizumab in combination wit ...... t of metastatic breast cancer.
@en
Bevacizumab in combination wit ...... t of metastatic breast cancer.
@nl
type
label
Bevacizumab in combination wit ...... t of metastatic breast cancer.
@en
Bevacizumab in combination wit ...... t of metastatic breast cancer.
@nl
prefLabel
Bevacizumab in combination wit ...... t of metastatic breast cancer.
@en
Bevacizumab in combination wit ...... t of metastatic breast cancer.
@nl
P2860
P356
P1433
P1476
Bevacizumab in combination wit ...... nt of metastatic breast cancer
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDQ122
P50
P577
2010-03-24T00:00:00Z